Drug Type Small molecule drug |
Synonyms 2-Iminobiotin, Guanidinobiotin, Hexahydro-2-imino-1h-thieno(3,4-d)imidazole-4-pentanoic acid + [2] |
Target |
Mechanism NOS2 inhibitors(Nitric oxide synthase, inducible inhibitors), nNOS inhibitors(Nitric-oxide synthase, brain inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC10H17N3O2S |
InChIKeyWWVANQJRLPIHNS-ZKWXMUAHSA-N |
CAS Registry13395-35-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypoxia-Ischemia, Brain | Phase 2 | NL | 01 May 2016 | |
Out-Of-Hospital Cardiac Arrest | Phase 2 | NL | 01 May 2016 | |
Perinatal asphyxia | Phase 2 | TR | 01 Jun 2012 |
Phase 3 | 93 | jlheodzfud(eqmvfzwkdf) = measured in logarithm of the minimum angle of resolution (logMAR) at 100% contrast of the selected eye uwdyxcwsqo (ihwqkugpzo ) | Negative | 01 Jul 2018 | |||
Placebo |